US OptionsDetailed Quotes

CERT250516C2500

Watchlist

11.80
0.000.00%

15min DelayClose May 6 15:59 ET

0.00High0.00Low

Certara Stock Discussion

Teddy123

Apr 14 20:38

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

$Certara (CERT.US)$
Revolutionary AI Platform Cuts Drug Development Costs by Replacing Animal Testing

Teddy123

Apr 14 20:17

Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization

$Certara (CERT.US)$
Certara Delivers Strong Q1: Software Revenue Surges 18%, Unveils Major Buyback Plan

SK111

Apr 11 16:18

$Certara (CERT.US)$ Hmm... A gap down

Jaguar8

Apr 11 05:39

🟡Watchlist, APRIL 11,2025, Friday. NFA - DrJag8

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...

Moomoo AI

Mar 21, 2024 22:18

The fact that Certara is now generating some pre-tax profits from its prior investments is very encouraging. The promising trends warrant this stock for further investigation despite its current low returns compared to the industry average.

Returns At Certara (NASDAQ:CERT) Are On The Way Up

Moomoo AI

Dec 14, 2023 05:33

Acquisition of Applied BioMath by Certara could enhance QSP biosimulation adoption in life sciences, revolutionizing drug invention. This may impact the drug discovery process, improving decisions and reducing late stage attrition rates.

Press Release: Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies

Moomoo AI

Oct 31, 2023 19:27

Amid less promising revenue projections, Certara's surprisingly high P/S ratio indicates investor hopes for a business rebound. However, analysts remain skeptical, suggesting shareholders may face disappointment if the P/S ratio rebalances with growth outlook.

Certara, Inc.'s (NASDAQ:CERT) Price Is Out Of Tune With Revenues

Movers and Shakers

Aug 22, 2023 20:21

Columns Today's Pre-Market Stock Movers And Top Ratings: ZM, LOW, EMR, MDT and More

Pre-Market Stock Movers
Gapping up
$Fabrinet (FN.US)$
(Fabrinet surged 21% after its fiscal fourth-quarter results late Monday topped analysts' estimates. The advanced manufacturing services company posted non-GAAP earnings of $1.86 per share, greater than the $1.80 earnings per share expected by analysts polled by FactSet. Revenue came in at $655.9 million, greater than the $641.4 million consensus estimate.)
$Applovin (APP.US)$
...